Ruffer LLP Cuts Stake in Supernus Pharmaceuticals, Inc. $SUPN

Ruffer LLP decreased its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 38.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 34,327 shares of the specialty pharmaceutical company’s stock after selling 21,058 shares during the period. Ruffer LLP’s holdings in Supernus Pharmaceuticals were worth $1,709,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Jefferies Financial Group Inc. boosted its stake in shares of Supernus Pharmaceuticals by 62.0% in the 3rd quarter. Jefferies Financial Group Inc. now owns 86,179 shares of the specialty pharmaceutical company’s stock valued at $4,118,000 after purchasing an additional 32,979 shares in the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter valued at $1,434,000. Phocas Financial Corp. purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at $4,042,000. Teacher Retirement System of Texas boosted its stake in shares of Supernus Pharmaceuticals by 648.9% in the 3rd quarter. Teacher Retirement System of Texas now owns 112,638 shares of the specialty pharmaceutical company’s stock valued at $5,383,000 after purchasing an additional 97,597 shares in the last quarter. Finally, VELA Investment Management LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter valued at $1,924,000.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on SUPN shares. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday, March 8th. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Zacks Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $62.17.

Supernus Pharmaceuticals Stock Up 2.4%

Shares of SUPN opened at $50.29 on Thursday. The stock has a market capitalization of $2.90 billion, a P/E ratio of -73.95, a PEG ratio of 1.53 and a beta of 0.73. The firm has a fifty day simple moving average of $51.34 and a two-hundred day simple moving average of $49.87. Supernus Pharmaceuticals, Inc. has a twelve month low of $29.16 and a twelve month high of $59.68.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, Director Georges Gemayel sold 8,787 shares of the stock in a transaction on Friday, March 6th. The shares were sold at an average price of $53.00, for a total transaction of $465,711.00. Following the completion of the sale, the director owned 27,277 shares of the company’s stock, valued at $1,445,681. This represents a 24.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jack A. Khattar sold 35,000 shares of the stock in a transaction on Friday, March 13th. The shares were sold at an average price of $50.37, for a total transaction of $1,762,950.00. Following the sale, the chief executive officer directly owned 958,100 shares of the company’s stock, valued at $48,259,497. The trade was a 3.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 120,881 shares of company stock worth $6,139,356 over the last ninety days. 8.80% of the stock is owned by company insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.